OTC Markets EXMKT - Delayed Quote USD

RVL Pharmaceuticals plc (RVLPQ)

Compare
0.0001 0.0000 (0.00%)
At close: October 21 at 4:00 PM EDT
Loading Chart for RVLPQ
DELL
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0345
  • Volume 600
  • Avg. Volume 316
  • Market Cap (intraday) 11,141
  • Beta (5Y Monthly) 26.78
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7100
  • Earnings Date Oct 28, 2024 - Nov 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

www.rvlpharma.com

125

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RVLPQ

View More

Performance Overview: RVLPQ

Trailing total returns as of 10/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RVLPQ
96.67%
S&P 500
21.80%

1-Year Return

RVLPQ
96.78%
S&P 500
37.77%

3-Year Return

RVLPQ
99.99%
S&P 500
27.83%

5-Year Return

RVLPQ
100.00%
S&P 500
93.37%

Compare To: RVLPQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RVLPQ

View More

Valuation Measures

Annual
As of 10/24/2024
  • Market Cap

    11.14k

  • Enterprise Value

    39.00M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.00

  • Price/Book (mrq)

    0.00

  • Enterprise Value/Revenue

    1.06

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -184.91%

  • Return on Assets (ttm)

    -23.65%

  • Return on Equity (ttm)

    -182.44%

  • Revenue (ttm)

    36.92M

  • Net Income Avi to Common (ttm)

    -68.27M

  • Diluted EPS (ttm)

    -0.7100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.16M

  • Total Debt/Equity (mrq)

    356.16%

  • Levered Free Cash Flow (ttm)

    -25.56M

Research Analysis: RVLPQ

View More

Company Insights: RVLPQ

Research Reports: RVLPQ

View More

People Also Watch